XNCR

Xencor (XNCR)

Xencor Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XNCR

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/11/27	06 : 01	Business Wire	Xencor to Participate at Upcoming Investor Conferences	NASDAQ:XNCR	Xencor Inc
2024/11/22	06 : 21	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:XNCR	Xencor Inc
2024/11/15	08 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XNCR	Xencor Inc
2024/11/15	08 : 16	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:XNCR	Xencor Inc
2024/11/14	07 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XNCR	Xencor Inc
2024/11/14	06 : 21	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:XNCR	Xencor Inc
2024/11/12	22 : 33	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:XNCR	Xencor Inc
2024/11/09	04 : 17	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:XNCR	Xencor Inc
2024/11/07	06 : 09	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XNCR	Xencor Inc
2024/11/07	06 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XNCR	Xencor Inc
2024/11/07	06 : 01	Business Wire	Xencor Reports Third Quarter 2024 Financial Results	NASDAQ:XNCR	Xencor Inc
2024/11/04	21 : 00	Business Wire	Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease	NASDAQ:XNCR	Xencor Inc
2024/10/22	05 : 18	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:XNCR	Xencor Inc
2024/10/19	04 : 31	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:XNCR	Xencor Inc
2024/10/10	21 : 09	Business Wire	Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases	NASDAQ:XNCR	Xencor Inc
2024/10/04	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XNCR	Xencor Inc
2024/10/04	21 : 01	Business Wire	Xencor Announces Upcoming Change to Board of Directors	NASDAQ:XNCR	Xencor Inc
2024/10/03	05 : 50	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:XNCR	Xencor Inc
2024/10/02	05 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XNCR	Xencor Inc
2024/10/02	05 : 10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XNCR	Xencor Inc
2024/10/02	05 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XNCR	Xencor Inc
2024/09/27	23 : 35	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:XNCR	Xencor Inc
2024/09/27	23 : 12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:XNCR	Xencor Inc
2024/09/27	22 : 41	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:XNCR	Xencor Inc
2024/09/13	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XNCR	Xencor Inc
2024/09/13	05 : 01	Business Wire	Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	NASDAQ:XNCR	Xencor Inc
2024/09/12	21 : 47	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XNCR	Xencor Inc
2024/09/12	21 : 45	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:XNCR	Xencor Inc
2024/09/11	19 : 31	Business Wire	Xencor Announces Pricing of $175 Million Public Offering of Common Stock	NASDAQ:XNCR	Xencor Inc
2024/09/11	05 : 34	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:XNCR	Xencor Inc